For the three months ended June 30, 2024, our Revenues, net were $13.9 million. For the same period, our time charter equivalent (“TCE”) revenues were $12.2 million, an increase of $3.6 million, or 41 ...
- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 ...
Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results